Business Context and Reporting Period
This Form 8-K Current Report was filed by RXi Pharmaceuticals Corporation (referred to in the metadata as Phio Pharmaceuticals Corp.) on May 28, 2015. The filing discloses the pricing and completion of a public offering of securities pursuant to registration statements on Form S-1 and Form S-1MEF.
Key Financial Metrics
The filing details a capital raise event rather than operational financial results. Key metrics from the offering include:
- Gross Proceeds: Approximately $10.4 million.
- Net Proceeds: Approximately $9.3 million (after placement agent fees and estimated expenses).
- Units Sold: 26,000,000 units.
- Offering Price: $0.40 per Unit.
- Placement Agent: H.C. Wainwright & Co., LLC (acting on a best efforts basis).
Operational metrics such as revenue, profit, cash flow, margins, and debt levels are not provided in this filing.
Material Changes and Offering Structure
The primary material change is the entry into a Material Definitive Agreement (Securities Purchase Agreement) to sell the securities. Each Unit sold consists of:
- One share of common stock.
- A 13-month overallotment purchase right to purchase one-half of one share at $0.455 per full share.
- A five-year warrant to purchase one-half of one share at $0.52 per full share.
The net proceeds figure assumes the overallotment purchase rights and warrants are not exercised.
Guidance, Outlook, and Risks
The filing does not contain management guidance, future outlook, or specific risk factors beyond the standard disclosure that the description of the Purchase Agreement is qualified by reference to the full text of the agreement. The company agreed to indemnify investors under the Purchase Agreement against certain liabilities.
Investor Verification Checklist
- Verify the final number of units sold if the overallotment purchase rights are exercised.
- Review the full text of the Securities Purchase Agreement (Exhibit 10.1) for specific covenants and termination provisions.
- Confirm the exact amount of placement agent fees and offering expenses deducted to reach the $9.3 million net proceeds.
- Check subsequent filings for the actual exercise of the 13-month overallotment rights and 5-year warrants.